Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs-Reference-Cited by-同舟云学术

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Published:2019-02 Issue:2 Volume:22 Page:220-224
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Clément Valérie,Raimond Véronique

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference54 articles.

1. France. Décret N° 2012-1116 Du 2 Octobre 2012 Relatif Aux Missions Médico-Économiques de La Haute Autorité de Santé; 2012.

2. Haute Autorité de Santé. Choices in Methods for Economic Evaluation. Saint-Denis la Plaine: HAS, 2012. 〈https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf〉. Accessed September 27, 2018.

3. The high price of the new hepatitis C virus drugs;Steinbrook;JAMA Intern Med,2014

4. Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy;Pho;Hepatology,2014

5. The price of good health;Anonymous;Nat Med,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE CONCEPT OF «SMART REGULATION» IN FOREIGN PUBLIC ADMINISTRATION STUDIES;Public Administration Issues;2023

2. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health;Bulletin du Cancer;2021-12

3. Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020;Value in Health;2021-12

4. Drug Price Regulation;Encyclopedia of Law and Economics;2020-11-27